Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

e products, patents and technologies acquired from ENI as well as the amortization of the NeuroMedix technology acquired May 9, 2007.

Interest income, net for the fiscal year ended June 30, 2007, was $1,226,099 as compared to $350,380 for the fiscal year ended June 30, 2006. The increase in interest income, net of $875,719 primarily resulted from increased cash balances due to the November 2006 private placement and the upfront payment received from Elan.

Recovery of future income taxes for the year ended June 30, 2007 increased by $1,631,901 or 149% to a recovery of $2,729,422 as compared to a recovery of $1,097,521 for the year ended June 30, 2006. The majority of the increase in recovery of future income taxes for fiscal 2007 is due to the recognition of future income tax assets resulting from the amalgamation of Ellipsis Neurotherapeutics Inc., 1255205 Ontario Inc., 1255206 Ontario Inc. and Waratah Pharmaceuticals Inc. As a result of the amalgamation, the Company has adjusted the valuation allowance on future income tax assets and has recognized a future income tax asset to the extent of offsetting future income tax liabilities of the amalgamated entity. Additional future income tax recovery also arose from changes in temporary differences.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit ht
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Comparemedicalinsurance.info has released a new blog ... who have health problems. , A pre-existing medical ... clients. No medical exam life insurance plans offer a ... a lot easier. , No medical exam life ... temporary protection, while others will insure the client for ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Discount-Dress.com, an ... and women’s special occasion outfits, is doing its best ... its dresses at discounted rates, up to 75% off. ... new blog . Also, it has unveiled many ... cocktail party dresses, gorgeous lace wedding dresses, purple prom ...
(Date:7/24/2014)... July 24, 2014 Follow ... a rapidly expanding sector in the in-vitro diagnostics ... collection devices, new detection technologies, computers, and automation ... versatility, and speed. In addition to disease diagnosis, ... benefits in patient stratification, drug regimen selection, therapeutic ...
(Date:7/24/2014)... Hanover, MA (PRWEB) July 24, 2014 ... Foundation will be on hand to provide educational and ... 11th Annual Meeting next week in Colorado Springs. , ... from some of the most renowned neurointerventional research ... problem solving and innovating together (with or at) symposiums, ...
(Date:7/24/2014)... July 24, 2014 “To care for him ... and his orphan.” The inspired quote is attributed to Abraham ... of Veterans Affairs (VA). And yet the reality of Lincoln’s ... in exchange for their service in times of conflict, leaves ... represents many veterans locked in a battle they never expected ...
Breaking Medicine News(10 mins):Health News:Life Insurance Without Examinations for Clients Who Have Pre-Existing Medical Conditions 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 4Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 5
... 19 DaVita Inc., a,leading provider of kidney ... (CKD) and kidney failure, today announced that they ... patients,against influenza (flu). Today,s announcement highlights DaVita,s proven ... services, setting the standard for,superior clinical care. , ...
... Lecture for Healthcare ProfessionalsVOORHEES, N.J., Jan. 19 ... being seen in older adults, especially among residents ... complicated by the emergence of a virulent strain ... rates of morbidity and mortality. Implementing strategies for ...
... Center invites women of all ages to attend Girls, ... 6:00 p.m. at Northgate Mall. The event, sponsored by ... more. The Northwest Hospital booth will feature free ... well as body mass index (BMI) and waist measurement ...
... Educational CD provides veterinarians with a new way to understanding and ... ... January 19, 2009 -- Merial today announced the availability of an ... the complex subject of heartworm prevention and treatment in dogs. Launched ...
... Inc., a world leader in handheld x-ray technologies, announced ... patent for its NOMAD Handheld X-ray System. The latest ... having all components of the x-ray system in the ... the world,s first handheld x-ray system. Aribex was previously ...
... Fla., Jan. 19 As the unemployment rate grows, ... who are coping with the,loss of health insurance. COBRA ... but while many workers have the right to,purchase such ... cost is,often prohibitively high. A November 2008 study by ...
Cached Medicine News:Health News:DaVita 'Flu Fighter Program' Vaccinates 85 Percent of Patients 2Health News:Clostridium difficile Infection in Long-Term Care: Tailored Approaches to Management 2Health News:Northwest Hospital Sponsors Girls' Day Out Event at Northgate Mall 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 3Health News:Aribex(R) Awarded Patents for Handheld X-ray 2Health News:Is Your Business Ready for the COBRA Premium Subsidy? 2
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: